Physician profile
Dawn Walker
NPI 1912468505
$3,642.20
in general payments reported to CMS, 2019-2025
23 companies · $823 in 2025
The $823 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3.07 · 2022: $108 · 2023: $502 · 2024: $2,206 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607 · Travel and Lodging: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,607.00 |
| Travel and Lodging | $924.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,483.34 | 2024 | Neurostar Tms Therapy System |
| Abbvie INC. | $852.91 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $229.42 | 2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.75 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $183.82 | 2023-2025 | Rexulti, Jynarque, Abilify Maintena |
| Axsome Therapeutics, INC. | $106.77 | 2025 | Auvelity |
| Lundbeck LLC | $88.40 | 2024-2025 | Rexulti |
| Dexcom, INC. | $60.29 | 2022-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $57.40 | 2023-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $54.04 | 2022-2023 | Verquvo, Belsomra |
| Teva Pharmaceuticals USA, INC. | $51.32 | 2023-2025 | Uzedy, Austedo Xr |
| Viatris Specialty LLC | $50.80 | 2025 | Yupelri |
| Astellas Pharma US INC | $36.03 | 2025 | Veozah |
| Lilly USA, LLC | $33.18 | 2023-2025 | Zepbound, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals Lp | $32.77 | 2023-2025 | Breztri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.69 | 2022-2023 | Otezla, Repatha |
| Pfizer INC. | $21.48 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.40 | 2024 | Trintellix |
| Sumitomo Pharma America, INC. | $16.42 | 2024 | Gemtesa |
| Collegium Pharmaceutical, INC. | $16.04 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $14.59 | 2024 | Qelbree |
| Quidel Corporation | $14.27 | 2023 | Triage |
| Genentech USA, INC. | $3.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.